Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Friday, May 27, 2016, 78 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.48 to $15,949,248.85.

Highlighted Stocks Traded by Insiders:

Insulet (PODD) - FREE Research Report

Sommer Regina O, who is Director at Insulet, sold 8,019 shares at $30.42 on May 27, 2016. Following this transaction, the Director owned 20,330 shares meaning that the stake was reduced by 28.29% with the 8,019-share transaction.

The shares most recently traded at $29.82, down $0.60, or 2.01% since the insider transaction. Historical insider transactions for Insulet go as follows:

  • 4-Week # shares bought: 49,631
  • 4-Week # shares sold: 8,019
  • 12-Week # shares bought: 49,631
  • 12-Week # shares sold: 8,019
  • 24-Week # shares bought: 52,861
  • 24-Week # shares sold: 15,682

The average volume for Insulet has been 560,800 shares per day over the past 30 days. Insulet has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are down 20.07% year-to-date as of the close of trading on Friday.

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. Currently, there are 9 analysts who rate Insulet a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PODD - FREE

TheStreet Quant Ratings rates Insulet as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, deteriorating net income, generally high debt management risk and feeble growth in its earnings per share. Get the full Insulet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Power Integrations (POWI) - FREE Research Report

Ademmer Wolfgang, who is VP, High Power Products at Power Integrations, sold 6,191 shares at $49.54 on May 27, 2016. Following this transaction, the VP, High Power Products owned 13,904 shares meaning that the stake was reduced by 30.81% with the 6,191-share transaction.

The shares most recently traded at $49.82, up $0.28, or 0.57% since the insider transaction. Historical insider transactions for Power Integrations go as follows:

  • 4-Week # shares sold: 14,913
  • 12-Week # shares sold: 14,913
  • 24-Week # shares sold: 30,699

The average volume for Power Integrations has been 138,000 shares per day over the past 30 days. Power Integrations has a market cap of $1.4 billion and is part of the technology sector and electronics industry. Shares are up 1.99% year-to-date as of the close of trading on Friday.

Power Integrations, Inc. designs, develops, and markets analog and mixed-signal integrated circuits (ICs), and other electronic components and circuitry used in high-voltage power conversion. The stock currently has a dividend yield of 1.05%. The company has a P/E ratio of 35.2. Currently, there are 3 analysts who rate Power Integrations a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on POWI - FREE

TheStreet Quant Ratings rates Power Integrations as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Power Integrations Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sunesis Pharmaceuticals (SNSS) - FREE Research Report

Parker Geoffrey M., who is Director at Sunesis Pharmaceuticals, bought 9,500 shares at $0.47 on May 27, 2016. Following this transaction, the Director owned 62,005 shares meaning that the stake was boosted by 18.09% with the 9,500-share transaction.

The shares most recently traded at $0.55, up $0.08, or 14.75% since the insider transaction. Historical insider transactions for Sunesis Pharmaceuticals go as follows:

  • 4-Week # shares bought: 62,005
  • 4-Week # shares sold: 569,954
  • 12-Week # shares bought: 62,005
  • 12-Week # shares sold: 569,954
  • 24-Week # shares bought: 62,005
  • 24-Week # shares sold: 569,954

The average volume for Sunesis Pharmaceuticals has been 201,400 shares per day over the past 30 days. Sunesis Pharmaceuticals has a market cap of $40.9 million and is part of the health care sector and drugs industry. Shares are down 47.61% year-to-date as of the close of trading on Friday.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Currently, there is 1 analyst who rates Sunesis Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNSS - FREE

TheStreet Quant Ratings rates Sunesis Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself. Get the full Sunesis Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant